|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Operating lease right-of-use asset, net | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Notes payable (Note 3F) | ||||||||||||||||||||
| Operating lease liability, current | ||||||||||||||||||||
| Promissory notes (Note 3G and Note 3H) | ||||||||||||||||||||
| Promissory notes | ||||||||||||||||||||
| Convertible promissory notes | ||||||||||||||||||||
| Derivative financial liabilities (Note 3G and Note 3H) | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-Current Liabilities | ||||||||||||||||||||
| Derivative financial liabilities | ||||||||||||||||||||
| Operating lease liability, non-current | ||||||||||||||||||||
| Loans from stockholders | ||||||||||||||||||||
| Total non-current liabilities | ||||||||||||||||||||
| Loans from stockholders | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Common Stock of $0.001 par value 250,000,000 shares authorized as of June 30, 2026 and as of December 31, 2025; 6,259,279 and 910,688 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Receipts on account of shares | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity (deficit) | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
Loading...
